Extraordinary General Meeting of March 8, 2023 results
Paris, France, March 10, 2023 – 7:00 p.m. CET
– The Extraordinary General Meeting of shareholders of Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, met, on second call in Paris on March 8, 2023 and adopted all the resolutions with approximately 97% of favorable votes, relating to the granting to the Board of Directors (i) of an authorization to effect of reducing the share capital within the framework of a capital reduction motivated by losses and by reducing the par value of the shares from 0.06 euro to 0.02 euro, (ii) an authorization to decide on a consolidation shares and (iii) all the financial delegations submitted to the vote of the General Meeting
1
.
Details of the votes appear on the Company’s website under the heading “General Meeting of Shareholders”.
About Pixium Vision
Pixium Vision
creates a world of bionic vision to allow those who have lost their sight to recover their visual perception and gain autonomy. Pixium Vision’s bionic vision systems are associated with surgery and a period of rehabilitation. The Prima System’s wireless photovoltaic subretinal micro-implant is in clinical testing in patients who initially lost sight due to retinal degeneration due to the dry form of age-related macular degeneration (dry AMD) . Pixium Vision works closely with university partners and some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, the Institute of Ocular Microsurgery (IMO) in Barcelona, the University Hospital in Bonn and the UPMC in Pittsburgh (Pennsylvania, USA). The Company is EN ISO 13485 certified and has received the “Innovative Company” qualification from Bpifrance.
For more information: http://www.pixium-vision.com/fr
Follow us on @PixiumVision; www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
contacts
|
Pixium Vision Offer Nonhoff Financial director [email protected] +33 1 76 21 47 68 |
Press relations LifeSci Advisors Sophie Baumont [email protected] +33 6 27 74 74 49 |
Investor Relations LifeSci Advisors Guillaume van Renterghem [email protected] +41 76 735 01 31 |
1
With the exception of the capital increase reserved for employees (11
th
resolution) which was not adopted
Attachment
Pixium Vision – AGE 8 03 2023 – CP post EGM- FR v2